2023-07-16 17:30:00
The first drug designed by artificial intelligence (AI), INS018_055, is progressing. The pharmaceutical product is moving forward in its clinical development journey. It is a beacon of hope in the fight once morest idiopathic pulmonary fibrosis.
Insilico Medicine, a pioneer in biotechnology, has made an announcement. Its treatment, INS018_055, developed thanks to theartificial intelligence (IA), has reached an important milestone. He passed the phase 1 clinical trials. Currently, he is engaged in phase 2. It specifically targets the idiopathic pulmonary fibrosis, which is a disorder of the lungs. By entering phase 2, it is getting closer to official approval and might soon be used in a clinical setting.
More and more AI at the service of medical research
Recently, Insilico used AI in an important mission linked to idiopathic pulmonary fibrosis. The objective of this experiment was toidentify new targets and D’develop an effective molecule once morest this problem. To this end, two main tools have been deployed.
PandaOmicsthe first tool, analyzes clinical and scientific data. Using advanced artificial intelligence techniques, it spots patterns, correlations and anomalies that are usually difficult to detect. This ability is essential. It makes it possible to understand the complex mechanisms of diseases and identify new therapeutic targets. This facilitates the development of more precise treatments.
Chemistry42, the second tool, generates new molecules. When fed with specific characteristics, Chemistry42 produces a series of molecules. These are then ranked according to their probability of success. INS018_055 is the 55th contestant in this series and is considered the more promising.
Challenges and progress of INS018_055 treatment for idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis is currently treated with drugs capable of reducing the worsening of symptoms. However, these fail to repair the damage or stop the progression of the disease. They also have unwanted side effects such as nausea, fatigue or headaches. That is why INS018_055 embodies an alternative that brings hope.
As pointed out Alexei Zhavoronkovif the preliminary results are confirmed, INS018_055 might overcome the limitations of existing therapies. Indeed, INS018_055 embodies a significant advance in the pharmaceutical field. Thanks to this technology, the discovery and development of the drug has been significantly accelerated.
note that INS018_055 is specifically engineered to target the mechanisms underlying idiopathic pulmonary fibrosis. This specificity suggests the possibility of a treatment capable of alleviating the symptoms of this condition. This medicine can also slow down or even reverse its evolution.
In addition, the use of artificial intelligence in drug development might lead to more precise treatments, with fewer side effects. In other words, they would significantly improve the quality of life of patients.
However, obstacles remain such as the need to recruit enough participants for the trials of phase 2 et 2 b, especially in the case of a rare disease. However, despite these challenges, the team remains optimistic regarding the future of the treatment and its potential. This advance might even change the perception of theIA in the domain of health.
SEE ALSO: When AI improves hospital patient satisfaction
Artificial intelligence makes it easier and faster to manufacture drugs
Alexei Zhavoronkov, CEO of Insilico Medicine, made an apt comparison. According to him, creating new drugs is like solve a complicated puzzle. Usually, scientists look for a biological target related to the disease. Then they create molecules to interact with this target. The goal is to curb the disease.
But AI is a game-changer. It offers impressive computing power. It can analyze huge amounts of data. This makes it possible to discover new targets and create therapeutic molecules more quickly and easily.
1689531183
#drug #created #artificial #intelligence #tested #humans
